πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 120 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11890289

Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat ad

Corcept Therapeutics Incorporated Β· Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11793810

Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulat

Corcept Therapeutics Incorporated Β· Granted Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11744837

Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with gl

Corcept Therapeutics Incorporated Β· Granted Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11684612

Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid rece

Corcept Therapeutics Incorporated Β· Granted Tue Jun 27 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 22 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11660295

Glucocorticoid receptor modulators to treat cervical cancer

Corcept Therapeutics Incorporated Β· Granted Tue May 30 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 25 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11648245

Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Corcept Therapeutics Incorporated Β· Granted Tue May 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 11 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11642331

Glucocorticoid receptor modulators to treat pancreatic cancer

Corcept Therapeutics Incorporated Β· Granted Tue May 09 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 04 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11610666

Systems and methods of managing treatment of a chronic condition by symptom tracking

Corcept Therapeutics Incorporated Β· Granted Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11590135

Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagoni

Corcept Therapeutics Incorporated Β· Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11590113

Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid rece

Corcept Therapeutics Incorporated Β· Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11576907

Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators

Corcept Therapeutics Incorporated Β· Granted Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11560379

Octahydro fused azadecalin glucocorticoid receptor modulators

Corcept Therapeutics Incorporated Β· Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11542238

Pyrimidine cyclohexenyl glucocorticoid receptor modulators

Corcept Therapeutics Incorporated Β· Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11524013

Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid r

Corcept Therapeutics Incorporated Β· Granted Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11464764

Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin

Corcept Therapeutics Incorporated Β· Granted Tue Oct 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11389432

Methods of treating cancer comprising administration of a glucocorticoid receptor modulato

Corcept Therapeutics Incorporated Β· Granted Tue Jul 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11370789

Octahydro fused azadecalin glucocorticoid receptor modulators

Corcept Therapeutics Incorporated Β· Granted Tue Jun 28 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11327083

Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome

Corcept Therapeutics Incorporated Β· Granted Tue May 10 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 05 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11285145

Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxe

Corcept Therapeutics Incorporated Β· Granted Tue Mar 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11268145

Methods for treating Cushing's syndrome

Corcept Therapeutics Incorporated Β· Granted Tue Mar 08 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11234971

Methods of treating cancer comprising administration of a glucocorticoid receptor modulato

Corcept Therapeutics Incorporated Β· Granted Tue Feb 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11213526

Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulat

Corcept Therapeutics Incorporated Β· Granted Tue Jan 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11202784

Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat ad

Corcept Therapeutics Incorporated Β· Granted Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11202787

Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucoc

Corcept Therapeutics Incorporated Β· Granted Tue Dec 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 16 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted